Inversely, targeted anti-RSPO3 treatment in a PTPRK-RSPO3 xenograft CRC model was shown to induce tumor differentiation whilst reducing growth, stem cell marker expression and canonical Wnt pathway activity [58]. Here, PTPRK is linked to colorectal carcinoma.